Author(s): Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM,
Abstract Share this page
Abstract BENCHMRK-1 and -2 are ongoing double-blind phase III studies of raltegravir in patients experiencing failure of antiretroviral therapy with triple-class drug-resistant human immunodeficiency virus infection. At week 96 (combined data), raltegravir (400 mg twice daily) plus optimized background therapy was generally well tolerated, with superior and durable antiretroviral and immunological efficacy, compared with optimized background therapy alone.
This article was published in Clin Infect Dis
and referenced in Journal of Pharmacogenomics & Pharmacoproteomics